Compound 15 was found to have strong anti-proliferative activities (EC50 = 28–861 nM) against diffuse large B-cell lymphoma cells containing an EZH2 activating mutation, while lymphoma cells without an EZH2 mutation are generally insensitive. Here, EZH2 is linked to diffuse large B-cell lymphoma.